These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20473700)
1. Superinfection during treatment of nosocomial infections with tigecycline. García-Cabrera E; Jiménez-Mejías ME; Gil Navarro MV; Gómez-Gómez MJ; Ortiz-Leyba C; Cordero E; Pachón J; Eur J Clin Microbiol Infect Dis; 2010 Jul; 29(7):867-71. PubMed ID: 20473700 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of superinfections during treatment with tigecycline. Katsiari M; Ntorlis K; Nteves I; Roussou Z; Platsouka ED; Maguina A J Chemother; 2016 Apr; 28(2):110-5. PubMed ID: 27077933 [TBL] [Abstract][Full Text] [Related]
3. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Garcia-Vidal C; Sanjuan G; Moreno-García E; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Fernandez-Pittol M; Pitart C; Inciarte A; Bodro M; Morata L; Ambrosioni J; Grafia I; Meira F; Macaya I; Cardozo C; Casals C; Tellez A; Castro P; Marco F; García F; Mensa J; Martínez JA; Soriano A; Clin Microbiol Infect; 2021 Jan; 27(1):83-88. PubMed ID: 32745596 [TBL] [Abstract][Full Text] [Related]
4. Tigecycline use in serious nosocomial infections: a drug use evaluation. Bassetti M; Nicolini L; Repetto E; Righi E; Del Bono V; Viscoli C BMC Infect Dis; 2010 Sep; 10():287. PubMed ID: 20920273 [TBL] [Abstract][Full Text] [Related]
5. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates. Martín-Gandul C; García-Cabrera E; Castillo-Ojeda E; Jiménez-Mejías ME J Antimicrob Chemother; 2012 Apr; 67(4):1048-9. PubMed ID: 22207597 [No Abstract] [Full Text] [Related]
6. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections. Maseda E; Denis SE; Riquelme A; Gilsanz F Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465 [TBL] [Abstract][Full Text] [Related]
7. Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use. Ulu-Kilic A; Alp E; Altun D; Cevahir F; Kalın G; Demiraslan H J Infect Dev Ctries; 2015 Mar; 9(3):309-12. PubMed ID: 25771470 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of tigecycline in the treatment of nosocomial infection in a hospital in Taiwan. Wu MT; Chen HY; Ou TY; Kuo LN; Cheng KJ; Lee WS Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1030-6. PubMed ID: 25345432 [TBL] [Abstract][Full Text] [Related]
9. Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. Chen LY; Chen TC; Chen YH; Lin CY; Lin WR; Lu PL J Microbiol Immunol Infect; 2011 Oct; 44(5):352-7. PubMed ID: 21524975 [TBL] [Abstract][Full Text] [Related]
10. [Differences in the use of tigecycline between ICU patients and non-ICU patients]. Alvarez-Lerma F; Blanco L; Rodríguez JA; Grau S; Conde-Estévez D; Luque S Rev Esp Quimioter; 2010 Jun; 23(2):63-71. PubMed ID: 20559603 [TBL] [Abstract][Full Text] [Related]
12. Comparative study of prescribing patterns of tigecycline for trial patients versus non-trial patients. Horscht JJ; Zimmermann JB; Weigand MA; Bruckner T; Martin EO; Hoppe-Tichy T; Swoboda S In Vivo; 2014; 28(4):589-94. PubMed ID: 24982227 [TBL] [Abstract][Full Text] [Related]
13. Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp. Moon SY; Peck KR; Chang HH; Kim SW; Heo ST; Son JS; Ryu SY; Moon C; Jung SI; Shin SY; Lee JA; Joung MK; Chung DR; Kang CI; Song JH Microb Drug Resist; 2012 Dec; 18(6):562-6. PubMed ID: 22775562 [TBL] [Abstract][Full Text] [Related]
14. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Carmeli Y; Castro J; Eliopoulos GM; Samore MH Antimicrob Agents Chemother; 2001 Jan; 45(1):275-9. PubMed ID: 11120977 [TBL] [Abstract][Full Text] [Related]
15. [Clinical experience with tigecycline in the treatment of nosocomial infections caused by isolates exhibiting prevalent resistance mechanisms]. Giménez MJ; García-Rey C; Barberán J; Aguilar L Rev Esp Quimioter; 2009 Mar; 22(1):48-56. PubMed ID: 19308747 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409 [TBL] [Abstract][Full Text] [Related]
17. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Chemaly RF; Hanmod SS; Jiang Y; Rathod DB; Mulanovich V; Adachi JA; Rolston KV; Raad II; Hachem RY Medicine (Baltimore); 2009 Jul; 88(4):211-220. PubMed ID: 19593226 [TBL] [Abstract][Full Text] [Related]
18. Re-defining tigecycline therapy. De Rosa FG; Corcione S; Di Perri G; Scaglione F New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055 [TBL] [Abstract][Full Text] [Related]
19. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital. Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904 [TBL] [Abstract][Full Text] [Related]
20. [Initial use of tigecycline in Argentina]. Curcio D; Fernández F; Duret F Rev Chilena Infectol; 2007 Dec; 24(6):497-9. PubMed ID: 18180827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]